Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK563400PMID: 33104323
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 1234423-95-0
Drug Levels and Effects
Summary of Use during Lactation
Tenapanor is essentially non-absorbed systemically, with undetectable plasma concentrations following oral administration. The minimal systemic absorption of tenapanor will not result in a clinically relevant exposure to breastfed infants. No special precautions are necessary.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tenapanor
CAS Registry Number
1234423-95-0
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.[Clin Exp Nephrol. 2017]A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers.Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson M. Clin Exp Nephrol. 2017 Jun; 21(3):407-416. Epub 2016 Jul 1.
- Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.[Clin Pharmacol Drug Dev. 2017]Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders.Johansson S, Leonsson-Zachrisson M, Knutsson M, Spencer AG, Labonté ED, Deshpande D, Kohler J, Kozuka K, Charmot D, Rosenbaum DP. Clin Pharmacol Drug Dev. 2017 Sep; 6(5):448-456. Epub 2016 Oct 26.
- Tenapanor administration and the activity of the H(+) -coupled transporter PepT1 in healthy volunteers.[Br J Clin Pharmacol. 2017]Tenapanor administration and the activity of the H(+) -coupled transporter PepT1 in healthy volunteers.Johansson S, Rosenbaum DP, Palm J, Stefansson B, Knutsson M, Lisbon EA, Hilgendorf C. Br J Clin Pharmacol. 2017 Sep; 83(9):2008-2014. Epub 2017 May 31.
- Review Lifitegrast.[Drugs and Lactation Database (...]Review Lifitegrast.. Drugs and Lactation Database (LactMed®). 2006
- Review Celecoxib.[Drugs and Lactation Database (...]Review Celecoxib.. Drugs and Lactation Database (LactMed®). 2006
- Tenapanor - Drugs and Lactation Database (LactMed®)Tenapanor - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...